Abstracts tagged "B cells"

Abstract Number: 643 • 2014 ACR/ARHP Annual Meeting
The Effect of TNF Inhibition on the Autoreactive B Cell Repertoire in SLE Prone Mice
Anne Davidson, Weiqing Huang and Ranjit Sahu, Autoimmunity and Musculoskeletal Diseases, Feinstein Institute for Medical Research, Manhasset, NY
Background/Purpose: TNF inhibitors are widely used for inflammatory diseases but often induce ANAs that sometimes progress to overt SLE. TNF deficient mice fail to generate…
Abstract Number: 1948 • 2014 ACR/ARHP Annual Meeting
A Dual Role for IFN-γ in Development of Peripheral B Cells in Lupus-Prone MRL/Lpr Mice
Takeshi Machida¹, Natsumi Sakamoto¹, Gary S. Gilkeson² and Hideharu Sekine¹, ¹Immunology, Fukushima Medical University School of Medicine, Fukushima, Japan, ²Department of Medicine, Division of Rheumatology, Medical University of South Carolina, Charleston, SC
Background/Purpose: It had been reported previously that IFN-gamma and IFN-gamma-receptor-1 (IFNGR1) were required for auto-Ab production and development of renal disease in lupus-prone MRL/lpr mice.…
Abstract Number: 1607 • 2014 ACR/ARHP Annual Meeting
B Cell and Neutrophil-Related Transcripts Predict and Characterize a Lupus Flare
Mikhail Olferiev¹, Kyriakos A. Kirou² and Mary K. Crow³, ¹Research, HSS, New York, NY, ²Hospital for Special Surgery, New York, NY, ³Department of Medicine, Hospital for Special Surgery, New York, NY
Background/Purpose Lupus flare reflects an increase of disease activity that is associated with significant morbidity and accumulation of tissue damage. Prediction and prevention of lupus…
Abstract Number: 646 • 2014 ACR/ARHP Annual Meeting
ONO-4059 – a Highly Potent and Dual Oral Inhibitor of Bruton’s Tyrosine Kinase (Btk) and Tec Kinase: Improves Anti-Nuclear Antibodies–mediated SLE in Mice
Yuko Ariza¹, Toshio Yoshizawa¹, Yoshiko Ueda¹, Masayuki Murata¹ and Kazuhito Kawabata², ¹Exploratory Research Laboratories 1, Ono Pharmaceutical Co., Ltd., Osaka, Japan, ²Discovery Research Laboratories 3, Ono Pharmaceutical Co., Ltd., Osaka, Japan
Background/Purpose: Systemic Lupus Erythematosus (SLE) is a complex and heterogeneous autoimmune disease associated with the over production of high affinity autoantibodies, mainly raised against nuclear…
Abstract Number: 1956 • 2014 ACR/ARHP Annual Meeting
Increased IL-6 Production By Effector B Cells in Giant Cell Arteritis and Polymyalgia Rheumatica
Kornelis S.M. van der Geest¹, Wayel H. Abdulahad², Gerda Horst³, Abraham Rutgers², Annemieke M.H. Boots⁴ and Elisabeth Brouwer⁵, ¹Dept. of Rheumatology and Clinical Immunology, University Medical Center Groningen, Groningen, Netherlands, ²Rheumatology and Clinical Immunology, University Medical Center Groningen, Groningen, Netherlands, ³University Medical Center Groningen, Groningen, Netherlands, ⁴Dept. of Rheumatology and Clinical Immunology, University of Groningen, University Medical Center Groningen, Groningen, Netherlands, ⁵Hanzeplein 1, UMCG, Groningen, Netherlands
Background/Purpose: The role of B cells in auto-immunity may extend beyond the production of auto-antibodies. B cells can influence T cell responses via antigen presentation…
Abstract Number: 1471 • 2014 ACR/ARHP Annual Meeting
TNFα Influences the Status of B and T Cells By Acting on BCR and TCR Pathways Via RasGRP1 and RasGRP3 Proteins
Marie-Laure Golinski¹, Martine Hiron², Céline Derambure², Clément Guillou¹, Manuel Fréret², Olivier Boyer³, Olivier Vittecoq⁴ and Thierry Lequerré⁵, ¹Inserm 905 & Institute for Biomedical Research, University of Rouen, Rouen, France, ²Inserm 905 & Institute for Biomedical Research, University of Rouen, Rouen, France, Rouen, France, ³Immunology, INSERM U905, University of Rouen, Rouen, France, ⁴Rheumatology, Department of Rheumatology, Rouen University Hospital & Inserm 905, Institute for Biomedical Research, University of Rouen, Rouen, France, ⁵1 Rue De Germont, Chu De Rouen, Rouen, France
Background/Purpose Rheumatoid arthritis (RA) is the most common inflammatory arthritis. B and T cells play a key role in the RA pathophysiology. RasGRP is a…
Abstract Number: 605 • 2014 ACR/ARHP Annual Meeting
Decreased Frequencies of Circulating Follicular Helper T Cell Counterparts and Plasmablasts in Ankylosing Spondylitis Patients Naïve for TNF Blockers
M. Belén Bautista-Caro¹, Irene Arroyo-Villa¹, Concepcion Castillo-Gallego¹, Eugenio De Miguel², Diana Peiteado¹, Chamaida Plasencia-Rodriguez¹, Alejandro Villalba¹, Paloma Sanchez-Mateos³, Amaya Puig-Kröger⁴, Emilio Martín-Mola¹ and Maria Eugenia Miranda-Carus¹, ¹Rheumatology, Hospital La Paz - IdiPaz, Madrid, Spain, ²Rheumatology, University Hospital La Paz - IdiPaz, Madrid, Spain, ³Immunology, Hospital Gregorio Marañon, Madrid, Spain, ⁴Laboratorio de Inmuno-Metabolismo, Hospital General Universitario Gregorio Marañón, Instituto de Investigación Sanitaria Gregorio Marañón, Madrid, Spain
Background/Purpose: Follicular helper T cells (Tfh), localized in lymphoid organs, promote B cell differentiation and function. Circulating CD4 T cells expressing CXCR5, ICOS and/or PD-1…
Abstract Number: 2980 • 2014 ACR/ARHP Annual Meeting
Genome-Wide DNA Methylation Analysis of CD19+ B Cells in Primary Sjögren’s Syndrome
Gunnel Nordmark¹, Juliana Imgenberg-Kreuz², Jonas Carlsson Almlöf², Jessica Nordlund², Roald Omdal³, Katrine B. Norheim³, Maija-Leena Eloranta⁴, Lars Rönnblom⁴ and Johanna K. Sandling², ¹Rheumatology, Department of Medical Sciences, Uppsala University, Uppsala, Sweden, ²Molecular Medicine and Science for Life Laboratory, Department of Medical Sciences, Uppsala University, Uppsala, Sweden, ³Clinical Immunology Unit, Department of Internal Medicine, Stavanger University Hospital, Stavanger, Norway, ⁴Department of Medical Sciences, SciLife Lab, Rheumatology, Uppsala University, Uppsala, Sweden, Uppsala, Sweden
Background/Purpose Increasing evidence suggests an epigenetic contribution to the pathogenesis of autoimmune diseases, including primary Sjögren’s Syndrome (pSS) (1). A genome-wide DNA methylation study in…
Abstract Number: 1952 • 2014 ACR/ARHP Annual Meeting
Elucidation of Molecular Mechanisms of Breg Induction in Autoimmune Diseases
Shun-ichiro Ota, Hiroaki Niiro, Naoko Ueki, Yuri Hirosaki, Hirofumi Tsuzuki, Kumiko Noda, Siamak Jabbarzadeh-Tabrizi, Atsushi Tanaka, Hiroki Mitoma, Mitsuteru Akahoshi, Yojiro Arinobu, Hiroshi Tsukamoto and Koichi Akashi, Department of Medicine and Biosystemic Science, Kyushu University Graduate School of Medical Sciences, Fukuoka, Japan
Background/Purpose The advent of B-cell depletion therapy in autoimmune diseases identifies a novel B cell population, referred to as regulatory B cells (Bregs), that exerts…
Abstract Number: 986 • 2014 ACR/ARHP Annual Meeting
Integrated Comprehensive Analysis of Immune Cell Subsets and Serum Protein Profile Identifies the Role of Pre-Germinal Center B Cells in Sjogren’s Syndrome Pathogenesis
Yoshiaki Kassai¹, Katsuya Suzuki², Rimpei Morita³, Maiko Takiguchi¹, Rina Kurisu¹, Takahiro Miyazaki¹, Akihiko Yoshimura³ and Tsutomu Takeuchi², ¹Inflammation Drug Discovery Unit, Takeda Pharmaceutical Company Limited, Kanagawa, Japan, ²Division of Rheumatology, Department of Internal Medicine, Keio University School of Medicine, Tokyo, Japan, ³Department of Microbiology and Immunology, Keio University School of Medicine, Tokyo, Japan
Background/Purpose Whole blood flow cytometric analysis and serum protein profiling were commonly utilized to characterize disease-specific alterations in a wide variety of autoimmune diseases. However,…
Abstract Number: L3 • 2014 ACR/ARHP Annual Meeting
Low Protein A20 Expression in Minor Salivary Glands Is Associated with Lymphoma Development in Primary Sjögren’s Syndrome
Svein Joar A. Johnsen¹, Einar Gudlaugsson², Ivar Skaland², Emiel Janssen², Malin V. Jonsson³, Lars Helgeland⁴, Ellen Berget⁵, Roland Jonsson⁶ and Roald Omdal¹, ¹Clinical Immunology Unit, Department of Internal Medicine, Stavanger University Hospital, Stavanger, Norway, ²Stavanger University Hospital, Stavanger, Norway, ³Department of Clinical Dentistry - Section for Oral and Maxillofacial Radiology, University of Bergen, Bergen, Norway, ⁴Haukeland University Hospital, Bergen, Norway, ⁵University of Bergen, Bergen, Norway, ⁶Broegelmann Research Laboratory, Department of Clinical Science, University of Bergen, Bergen, Norway
Background/Purpose: Patients with primary Sjogrens syndrome (pSS) have an increased risk of developing lymphomas, especially of the subtype mucosa-associated lymphoid tissue (MALT) lymphoma. Chronic antigen…
Abstract Number: 2870 • 2014 ACR/ARHP Annual Meeting
B Cell-Intrinsic Deletion of the Type 1 Interferon Receptor Does Not Impact the Development of Murine Lupus
Shaun W. Jackson^1,2, Nicole Scharping¹, Socheath Khim¹ and David Rawlings^1,2, ¹Seattle Children's Research Institute, Seattle, WA, ²Pediatrics, University of Washington, Seattle, WA
Background/Purpose Type 1 interferon (IFN) is strongly implicated in lupus pathogenesis, and patients with SLE frequently express a “type 1 IFN gene signature”. Type 1…
Abstract Number: 1947 • 2014 ACR/ARHP Annual Meeting
Prolactin Promotes Survival of Immature B Cells from MRL/Lpr Mice
Karina Chavez-Rueda¹, Rocio Flores-Fernández¹, Francisco Blanco-Favela¹, María Legorreta-Haquet², Luis Chávez-Sánchez², Rafael Hernández-González³ and Emiliano Tesoro-Cruz³, ¹UIM en Inmunologia, IMSS, Mexico DF, Mexico, ²IMSS, Mexico DF, Mexico, ³Departamento de Investigación Experimental y Bioterio, Instituto Nacional de Ciencias Médicas y Nutrición, Mexico DF, Mexico
Background/Purpose Prolactin (PRL) plays an important role in modulating the immune response. PRL is secreted by the pituitary gland as well as many other organs…
Abstract Number: 1000 • 2014 ACR/ARHP Annual Meeting
Pathogenic Role of CXC Chemokine receptor 3-Positive B Cells in Bone Destruction of Rheumatoid Arthritis
Yuri Hirosaki, Hiroaki Niiro, Shun-ichiro Ota, Naoko Ueki, Hirofumi Tsuzuki, Kumiko Noda, Siamak Jabbarzadeh-Tabrizi, Hiroki Mitoma, Yojiro Arinobu, Mitsuteru Akahoshi, Hiroshi Tsukamoto and Koichi Akashi, Department of Medicine and Biosystemic Science, Kyushu University Graduate School of Medical Sciences, Fukuoka, Japan
Background/Purpose ：B cells can function as potent effector cells by production of autoantibody, immune complex formation and inflammatory cytokines. Clinical efficacy of B-cell depletion therapy…
Abstract Number: 2872 • 2014 ACR/ARHP Annual Meeting
B-Cell Autoepitope and Tetramer Analysis Reveals Expansion of Apoptotic Autoantigen La and snRNP Reactive B Cells in BXD2 Mice
Jennie Hamilton¹, Jun Li², Qi Wu³, PingAr Yang³, Bao Luo³, Hao Li⁴, Troy Randall⁵, John Edwin Bradley⁵, Justin J. Taylor⁶, John D. Mountz^7,8 and Hui-Chen Hsu^3,4, ¹University of Alabama at Birmingham, Birmingham, AL, ²Med - Immunology/Rheumatology, University of Alabama at Birmingham, Birmingham, AL, ³Division of Clinical Immunology and Rheumatology, Department of Medicine, University of Alabama at Birmingham, Birmingham, AL, ⁴Department of Medicine, Clinical Immunology & Rheumatology, University of Alabama at Birmingham, Birmingham, AL, ⁵Division of Clinical Immunology and Rheumatology, University of Alabama at Birmingham, Birmingham, AL, ⁶Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, WA, ⁷Dept of Med/Rheumatology Div, University of Alabama at Birmingham, Birmingham, AL, ⁸Birmingham VA Medical Center, Birmingham, AL
Background/Purpose Systemic lupus erythematous (SLE) is characterized by production of highly pathogenic IgG autoantibodies (autoAbs). While serum autoAb profiling is standard, it remains challenging to…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

ACR Abstract Embargo Policy

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. Academic institutions, private organizations and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part a scientific presentation or presentation of additional new information that will be available at the time of the meeting) is under embargo until Saturday, November 11, 2023.

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying financial and other sponsors about this policy. If you have questions about the abstract embargo policy, please contact the public relations department at [email protected].

Copyright Policy

View ACR Policies.